Innate Pharma
IPHA
10 hedge funds and large institutions have $282K invested in Innate Pharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
11% more funds holding
Funds holding: 9 → 10 (+1)
11% more capital invested
Capital invested by funds: $255K → $282K (+$26.8K)
0.02% more ownership
Funds ownership: 0.17% → 0.19% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.7K |
| 4 |
GI
GAMMA Investing
Foster City,
California
|
+$4.36K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$28.5K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$828 |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$368 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ETC
1
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $112K | -$28.5K | -14,598 | -19% |
|
2
Morgan Stanley
New York
| $77.5K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $43.2K | +$24.2K | +12,414 | +105% |
|
|
4
Millennium Management
New York
| $27.3K | +$29.9K | +15,326 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $16K | +$10.7K | +5,491 | +156% |
|
|
GI
6
GAMMA Investing
Foster City,
California
| $3.98K | +$4.36K | +2,233 | New |
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $1.2K | – | – | – |
|
8
Barclays
London,
United Kingdom
| $546 | – | – | – |
|
9
Optiver Holding
Amsterdam,
Netherlands
| $180 | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $5 | +$6 | +3 | New |
|
|
11
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$828 | -450 | Closed |
|
|
SPIA
12
Steward Partners Investment Advisory
New York
| – | -$368 | -200 | Closed |
|
IPHA Hedge Fund Activity: Q1 2025 in Review
10 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2025, worth a combined $282K — up 11% from $255K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IPHA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $29.9K. The largest seller was Exchange Traded Concepts, cutting an estimated $28.5K.
- 10 institutional investors held Innate Pharma (IPHA) as of Q1 2025, up from 9 in Q4 2024.
- Funds reported $282K of Innate Pharma stock for Q1 2025, up 11% quarter-over-quarter.
- 3 funds opened new Innate Pharma positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Innate Pharma buyer in Q1 2025 was Millennium Management, an estimated $29.9K added.
- The largest Innate Pharma seller in Q1 2025 was Exchange Traded Concepts, an estimated $28.5K sold.
Based on aggregated 13F filings for Q1 2025.